In the field of nuclear medicine, it is necessary to perfect non-invasive diagnostic methods, and PulmoBioTech is contributing greatly to this need. The company recently announced the completion of bio-distribution studies concerning its PulmoBind molecular imaging agent.

The process of imaging on a cellular level requires the use of specialized molecules which are chemically engineered to bind to specific cells in the body, and these are then bonded to radioactive tracers. PulmoBind is a bonding agent that has been found to surpass those traditionally used in the field on several points. Essentially, it is a totally harmless substance known as adreno medullin which, upon injection, travels to and bonds with the tissue in the lungs more effectively than commonly used albumin macro-aggregates (AMAs). PulmoBind is safer as well, and provides the ability to capture images that are not possible with the older method.

Perhaps the best reason

...

Pacific Growth Equities’ Analyst Yun Kim recommends Bankrate (RATE) based on the following: 1. Bankrate, Inc. and its subsidiaries own and operate an Internet-based consumer banking and personal finance network. Its Web site, Bankrate.com aggregates information on mortgages, credit cards, automobile loans, money market accounts, certificates of deposit, checking and ATM fees, home equity loans, and online banking fees.

2. The assumption that there will likely be a surge in demand for deposits this year as many major banks are looking to boost their deposits in anticipation of write-downs of bad credit-card debt and home-equity loans.

3. According to Kim, there currently isn’t much online infrastructure to support a surge in demand, and that there aren’t any established players in this area of consumer finance, except for Bankrate.

4. The expected strength in its deposits business can more than offset this volatility.

5. The stock currently trades at 13.2 times

...